Introduction: Because invasive fungal infections cause significant morbidity and mortality in liver transplant recipients, the use of antifungal prophylaxis, and the early empirical use of antifungal agents, is widespread on liver transplant units. The new-generation azoles such as voriconazole and the echinocandins have been welcome additions to the antifungal armamentarium. These agents have become the leading options for prophylaxis in liver transplant units, despite the absence of strong data for their efficacy in this setting.Clinical Picture: We report two recipients of living-donor liver transplants who became infected/colonised with fungi resistant to an echinocandin and the azoles after exposure to these agents. One patient developed trichosporonosis while on caspofungin and the other became infected/ colonised with Candida glabrata that was resistant to voriconazole and posaconazole. Conclusion: We report these to highlight some of the consequences of using the newer antifungal agents.
Invasive fungal infections (IFI) are associated with a high mortality in liver transplant recipients. The incidence of fungal infections after liver transplantation ranges from 7% to 42%, with Candida sp. and Aspergillus sp. being the commonest pathogens. A prophylactic strategy against fungi is therefore attractive, and is practised in many liver transplant units. In a meta-analysis, prophylaxis reduced the total number of proven fungal infections, and mortality attributable to fungal infections, but it did not improve overall mortality.
This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.